MedTrace Logo

Study of VIR-2482 in Healthy Volunteers

NCT04033406 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-06-09

No results posted yet for this study

Summary

This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.

Conditions

Interventions

DRUG

VIR-2482

VIR-2482 given by intramuscular injection

DRUG

Placebo

Sterile normal saline (0.9% NaCl) given by intramuscular injection

Sponsors & Collaborators

  • Vir Biotechnology, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2021-11-01
Completion
2021-11-01
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04033406 on ClinicalTrials.gov